MIMS September prescribing update
- Vismodegib (Erivedge) is a low molecular weight, orally available inhibitor of the Hedgehog pathway.
The Hedgehog pathway signalling through the smoothened transmembrane protein (SMO) leads to the activation and nuclear localisation of GLI transcription factors and induction of Hedgehog target genes.
Vismodegib binds to and inhibits SMO, thereby preventing Hedgehog signal transduction.
It is indicated for the